Drug Profile
MK 6913
Alternative Names: MK-6913Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Karo Bio; Merck & Co
- Class
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Female genital diseases
- Discontinued Vasomotor symptoms
Most Recent Events
- 31 Jul 2013 No development reported - Phase-I for Gynaecological disorders (unspecified route)
- 30 Sep 2012 Merck and Karo Bio terminate their collaboration on estrogen receptors
- 04 Apr 2012 Phase-I clinical trials in Female genital diseases (unspecified route)